Reintervention-study After Previous Renal Denervation in Non-responding Patients With Severe Hypertension

Reintervention After Previous Renal Denervation in Non-responding Patients With Severe Hypertension

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01834118

Acronym

RETREAT

Enrollment

Registered

2013-04-17

Start date

2013-06-30

Completion date

2016-04-30

Last updated

2016-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Resistant to Conventional Therapy

Brief summary

The purpose of this study is to determine the effect of repeated renal denervation in non-responding patients with severe hypertension. Therefore ultrasound technique will be used.

Detailed description

Renal Denervation is a CE-certified opportunity for treating patients with therapy-refractory hypertension. In some patients it doesn't show a significant lowering of the blood pressure, so a repeated renal denervation is an option. In this study repeated renal denervation will be performed with the Recor Paradise Ultrasound Catheter. For the study no specific procedures are required which would exceed the standard renal denervation procedure with the CE-certified Recor Paradise Ultrasound Catheter System. There are no additional risks for the patient in consequence of participating in the study or the follow up procedures.

Interventions

PROCEDURERenal Denervation

Sympathetic nerve ablation via transcatheter renal denervation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Individual is ≥18 years old * Individual received renal denervation ≥12 months prior to study participation to no therapeutical avail and is scheduled for reintervention. * Systolic Office based blood pressure ≥140mmHg * Individual receives 3 or more antihypertensive drugs including one diuretic * Individual is willing to provide written informed consent to participate in this study

Exclusion criteria

* Individual has hypertension secondary to an identifiable and treatable cause * Individual has any serious medical condition which in the opinion of the investigator may adversely affect the participation. * Individual is pregnant, nursing or planning to be pregnant * Renal artery abnormalities which may affect the procedure

Design outcomes

Primary

Measure	Time frame
Office Blood pressure measurement	up to1 year

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026